Hanaa Mostafa El-Karaksy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hanaa Mostafa El-Karaksy has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Engy Adel Mogahed
Department of Pediatrics, Cairo University, Cairo, Egypt
7 shared publications - Mona Saeed El-Raziky
Department of Pediatrics, Kasr Alainy Medical School, Cairo University, Cairo, Egypt
5 shared publications - Fatma El-Mougy
Department of Clinical and Chemical Pathology, Cairo University, Cairo, Egypt
2 shared publications Haytham Ghita
2 shared publicationsMahmoud Besheer
Department of Pediatrics, Kasr Alainy Medical School, Cairo University, Cairo, Egypt
2 shared publications- Normeen Hany Rady
Department of Clinical Pathology, Faculty of Medicine, Cairo University, Egypt
2 shared publications
Latest Publications
- Open Access
- 27 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (12)
Generic vs brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children
BACKGROUND Direct acting antivirals have revolutionized hepatitis C virus (HCV) treatment. However, the high price of the brand forms is a barrier for their use in resource limited countries as Egypt. AIM To assess the safety and efficacy of the generic sofosbuvir (SOF)/ledipasvir (LED) in Egyptian HCV-infected children and to compare the results with the brand form. METHODS This analytical retrospective study included HCV infected children and adolescents aged 12-18 years or weighing > 35 kg. Collected data included: Age, sex, risk factors of HCV acquisition, comorbidities, liver functions, HCV viral load, degree of hepatic fibrosis, sustained virologic response (SVR) and frequency of treatment adverse effects. Patients who received the generic form of SOF/LED (Ledisbuvir) were compared to patients who received the brand form (Harvoni®) regarding SVR and frequency of adverse events. RESULTS The study included 43 patients who received Ledisbuvir and 73 who received Harvoni®. All patients achieved SVR. Treatment side effects were mild, transient and comparable in both groups. CONCLUSION The use of generic SOF/LED in HCV infected children is safe and effective. It is comparable to the brand form at a reduced price and represents an affordable and effective alternative.
- 27 December 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (12)
Open AccessGeneric vs brand forms of direct acting antivirals for hepatitis C virus treatment in Egyptian children
BACKGROUND Direct acting antivirals have revolutionized hepatitis C virus (HCV) treatment. However, the high price of the brand forms is a barrier for their use in resource limited countries as Egypt. AIM To assess the safety and efficacy of the generic sofosbuvir (SOF)/ledipasvir (LED) in Egyptian HCV-infected children and to compare the results with the brand form. METHODS This analytical retrospective study included HCV infected children and adolescents aged 12-18 years or weighing > 35 kg. Collected data included: Age, sex, risk factors of HCV acquisition, comorbidities, liver functions, HCV viral load, degree of hepatic fibrosis, sustained virologic response (SVR) and frequency of treatment adverse effects. Patients who received the generic form of SOF/LED (Ledisbuvir) were compared to patients who received the brand form (Harvoni®) regarding SVR and frequency of adverse events. RESULTS The study included 43 patients who received Ledisbuvir and 73 who received Harvoni®. All patients achieved SVR. Treatment side effects were mild, transient and comparable in both groups. CONCLUSION The use of generic SOF/LED in HCV infected children is safe and effective. It is comparable to the brand form at a reduced price and represents an affordable and effective alternative.
- 1 June 2018
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 70 (4) , 360-364
Helicobacter pylori infection in children with portal hypertensive gastropathy
Article: Helicobacter pylori infection in children with portal hypertensive gastropathy - Minerva Pediatrica 2018 August;70(4):360-4 - Minerva Medica - Journals
- 1 June 2018
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 70 (4) , 360-364
Helicobacter pylori infection in children with portal hypertensive gastropathy
Article: Helicobacter pylori infection in children with portal hypertensive gastropathy - Minerva Pediatrica 2018 August;70(4):360-4 - Minerva Medica - Journals
- 1 January 2018
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 70 (1) , 35-45
Focal hepatic lesions in Egyptian infants and children: the pediatric hepatologist perspective
Article: Focal hepatic lesions in Egyptian infants and children: the pediatric hepatologist perspective - Minerva Pediatrica 2018 February;70(1):35-45 - Minerva Medica - Journals
- 1 January 2018
- Published by Edizioni Minerva Medica in Minerva Pediatrics
- Vol. 70 (1) , 35-45
Focal hepatic lesions in Egyptian infants and children: the pediatric hepatologist perspective
Article: Focal hepatic lesions in Egyptian infants and children: the pediatric hepatologist perspective - Minerva Pediatrica 2018 February;70(1):35-45 - Minerva Medica - Journals
- 1 June 2017
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 18 (2) , 108-113
Ocular findings in patients with cholestatic disorders of infancy: A single-centre experience
- 1 June 2017
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 18 (2) , 108-113
Ocular findings in patients with cholestatic disorders of infancy: A single-centre experience
- 1 December 2016
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 17 (4) , 168-175
Blind percutaneous liver biopsy in infants and children: Comparison of safety and efficacy of percussion technique and ultrasound assisted technique
- 1 December 2016
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 17 (4) , 168-175
Blind percutaneous liver biopsy in infants and children: Comparison of safety and efficacy of percussion technique and ultrasound assisted technique
- 1 December 2016
- Published by Elsevier in Human Immunology
- Vol. 77 (12) , 1248-1253
Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection
- 1 December 2016
- Published by Elsevier in Human Immunology
- Vol. 77 (12) , 1248-1253
Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection
- 15 November 2016
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 13 (1) , 70-75
A pilot study using lactulose in management of minimal hepatic encephalopathy in children with extrahepatic portal vein obstruction
Minimal hepatic encephalopathy (MHE) is not associated with overt neuropsychiatric symptoms but rather with subtle changes in psychometric and/or neurophysiologic tests. We aimed to diagnose MHE in children with extrahepatic portal vein obstruction (EHPVO) and to evaluate the effect of lactulose on MHE. A prospective study was carried out on 30 patients with EHPVO (21 males; mean age 10±2.5 years). The study was carried out in the Pediatric Hepatology Unit, Cairo University Pediatric Hospital, Cairo, Egypt, between 2011 and 2013. All patients were subjected to clinical and laboratory assessment, neuropsychmetric testing using the arabic version of Wechsler intelligence tests, neurophysiological testing by visual electroencephalogram and P300 event related potentials (ERP). The prevalence of MHE among children with EHPVO was 20% (6/30). After randomization to treatment and no-treatment groups using lactulose, all tests were repeated after three months. Among four patients with MHE who received lactulose, three (75%) improved. On the other hand, one of the patients in the no-treatment group developed MHE. Only one patient in the treatment arm had to discontinue lactulose because of severe diarrhea. This pilot study revealed that the prevalence of MHE was 20%. Improvement on psychometic tests was seen in 75% of our patients (3/4) after treatment with lactulose. Lactulose treatment was well tolerated.
- 15 November 2016
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 13 (1) , 70-75
A pilot study using lactulose in management of minimal hepatic encephalopathy in children with extrahepatic portal vein obstruction
Minimal hepatic encephalopathy (MHE) is not associated with overt neuropsychiatric symptoms but rather with subtle changes in psychometric and/or neurophysiologic tests. We aimed to diagnose MHE in children with extrahepatic portal vein obstruction (EHPVO) and to evaluate the effect of lactulose on MHE. A prospective study was carried out on 30 patients with EHPVO (21 males; mean age 10±2.5 years). The study was carried out in the Pediatric Hepatology Unit, Cairo University Pediatric Hospital, Cairo, Egypt, between 2011 and 2013. All patients were subjected to clinical and laboratory assessment, neuropsychmetric testing using the arabic version of Wechsler intelligence tests, neurophysiological testing by visual electroencephalogram and P300 event related potentials (ERP). The prevalence of MHE among children with EHPVO was 20% (6/30). After randomization to treatment and no-treatment groups using lactulose, all tests were repeated after three months. Among four patients with MHE who received lactulose, three (75%) improved. On the other hand, one of the patients in the no-treatment group developed MHE. Only one patient in the treatment arm had to discontinue lactulose because of severe diarrhea. This pilot study revealed that the prevalence of MHE was 20%. Improvement on psychometic tests was seen in 75% of our patients (3/4) after treatment with lactulose. Lactulose treatment was well tolerated.
- 1 June 2016
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 17 (2) , 105-109
Haemophagocytic lymphohistiocytosis presenting as neonatal liver failure: A case series
- 1 June 2016
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 17 (2) , 105-109
Haemophagocytic lymphohistiocytosis presenting as neonatal liver failure: A case series
- 25 September 2015
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 36 (1) , 1-8
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children
Combined treatment with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV) is the only currently approved treatment for hepatitis C virus (HCV) infection in children. The aim of this study was to assess the safety and efficacy of combined treatment with PEG-IFN-α2b and RBV in Egyptian children and adolescents with genotype 4 (GT4) HCV infection. The study included 66 patients (3–17 years of age), of both sexes, infected with HCV GT4, treated with PEG-IFN-α2b (60 μg/m 2 ), subcutaneously once weekly plus RBV (15 mg/kg/day) in 2 divided oral doses. Efficacy was assessed by achievement of sustained virological response (SVR). Safety was assessed by questionnaires directed to the patients at specific intervals, growth assessment and laboratory tests. SVR was achieved in 28 patients (42.4%). Nonresponders had significantly commoner history of treated malignancies ( P = 0.03), baseline lower absolute neutrophil count (ANC; P = 0.009), higher gamma glutamyl transpeptidase (GGT; P = 0.003), and higher viral load ( P = 0.03). Fever was the most frequently reported side effect occurring in 98.5% of the patients followed by musculoskeletal symptoms. Neutropenia was observed in 36 patients (54.6%) and necessitated treatment discontinuation in 1 patient. Decline in both weight and height percentiles was observed in 70% of children who received the combined therapy for a total of 48 weeks. In conclusion, the currently available treatment for HCV GT4 in pediatric patients has modest SVR with numerous adverse events necessitating meticulous monitoring to optimize care of the patients. Side effects could be managed with dose modifications and specific treatment when necessary.
- 25 September 2015
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 36 (1) , 1-8
Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children
Combined treatment with pegylated interferon (PEG-IFN)-α2b and ribavirin (RBV) is the only currently approved treatment for hepatitis C virus (HCV) infection in children. The aim of this study was to assess the safety and efficacy of combined treatment with PEG-IFN-α2b and RBV in Egyptian children and adolescents with genotype 4 (GT4) HCV infection. The study included 66 patients (3–17 years of age), of both sexes, infected with HCV GT4, treated with PEG-IFN-α2b (60 μg/m 2 ), subcutaneously once weekly plus RBV (15 mg/kg/day) in 2 divided oral doses. Efficacy was assessed by achievement of sustained virological response (SVR). Safety was assessed by questionnaires directed to the patients at specific intervals, growth assessment and laboratory tests. SVR was achieved in 28 patients (42.4%). Nonresponders had significantly commoner history of treated malignancies ( P = 0.03), baseline lower absolute neutrophil count (ANC; P = 0.009), higher gamma glutamyl transpeptidase (GGT; P = 0.003), and higher viral load ( P = 0.03). Fever was the most frequently reported side effect occurring in 98.5% of the patients followed by musculoskeletal symptoms. Neutropenia was observed in 36 patients (54.6%) and necessitated treatment discontinuation in 1 patient. Decline in both weight and height percentiles was observed in 70% of children who received the combined therapy for a total of 48 weeks. In conclusion, the currently available treatment for HCV GT4 in pediatric patients has modest SVR with numerous adverse events necessitating meticulous monitoring to optimize care of the patients. Side effects could be managed with dose modifications and specific treatment when necessary.